deltatrials
Completed PHASE1/PHASE2 NCT00034684

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia

Sponsor: Merck Sharp & Dohme LLC

Conditions Blast Crisis Leukemia Leukemia, Lymphocytic Leukemia, Myeloid, Chronic Myelodysplastic Syndromes
Interventions Farnesyl Protein Transferase Inhibitor
Updated 6 times since 2017 Last updated: Jun 16, 2015 Started: Jul 31, 2001 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

A PHASE1/PHASE2 clinical study on Blast Crisis and Leukemia, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jul 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.